BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar P, Sah AK, Tripathi G, Kashyap A, Tripathi A, Rao R, Mishra PC, Mallick K, Husain A, Kashyap MK. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Mol Cell Biochem 2021;476:553-74. [PMID: 33029696 DOI: 10.1007/s11010-020-03924-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Verma HK, Bhaskar L. SARS-CoV-2 infection in people with pre-existing liver disease: Further research is warranted. World J Gastroenterol 2021; 27(45): 7855-7858 [PMID: 34963747 DOI: 10.3748/wjg.v27.i45.7855] [Reference Citation Analysis]
2 Husain A. A novel approach to minimize the false negative COVID-19 diagnosis by inclusion of specific cell markers and multiple sample collection. MethodsX 2021;8:101270. [PMID: 33614422 DOI: 10.1016/j.mex.2021.101270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 El-Shahat RA, El-Demerdash RS, El Sherbini ES, Saad EA. HCl-induced acute lung injury: a study of the curative role of mesenchymal stem/stromal cells and cobalt protoporphyrin. J Genet Eng Biotechnol 2021;19:41. [PMID: 33721136 DOI: 10.1186/s43141-021-00139-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M, Raya-Álvarez E, Velloso-Feijoó ML, López-Medina C, Ramos-Giraldez C, Godoy-Navarrete FJ, Redondo-Rodríguez R, Cabezas-Lucena AM, Morales-Águila M, Romero-Barco CM, Fernández-Nebro A. Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia. Reumatol Clin (Engl Ed) 2021:S2173-5743(21)00162-3. [PMID: 34538612 DOI: 10.1016/j.reumae.2021.02.006] [Reference Citation Analysis]
5 Ulayya AH, Mubarok AZ, Widodo W, Widjanarko SB, Marlita M. The Importance of Natural ACE2 Inhibitor: Potency of Porang (Amorphophallus muelleri) Glucomannan as Anti-SARS-Cov-2. ELECTRON J GEN MED 2022;19:em340. [DOI: 10.29333/ejgm/11402] [Reference Citation Analysis]
6 Chawla U, Kashyap MK, Husain A. Aging and diabetes drive the COVID-19 forwards; unveiling nature and existing therapies for the treatment. Mol Cell Biochem 2021. [PMID: 34169437 DOI: 10.1007/s11010-021-04200-7] [Reference Citation Analysis]
7 Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci 2021;17:8-19. [PMID: 33390829 DOI: 10.7150/ijbs.52569] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
8 Chawla U, Kashyap MK, Husain A. Aging and diabetes drive the COVID-19 forwards; unveiling nature and existing therapies for the treatment. Mol Cell Biochem 2021;476:3911-22. [PMID: 34169437 DOI: 10.1007/s11010-021-04200-7] [Reference Citation Analysis]
9 Kebria MM, Milan PB, Peyravian N, Kiani J, Khatibi S, Mozafari M. Stem cell therapy for COVID-19 pneumonia. Mol Biomed 2022;3:6. [PMID: 35174448 DOI: 10.1186/s43556-021-00067-8] [Reference Citation Analysis]
10 Biberoğlu S, İpekci A, İkizceli İ, Çakmak F, Akdeniz YS, Kanbakan A, Konukoğlu D, Bolayırlı İM, Börekçi Ş, Ürkmez S, Özkan S. Role of plasma angiotensin II and angiotensin-converting enzyme 2 levels on prognosis and mortality in hypertensive patients with COVID-19. Biomark Med 2021;15:1581-8. [PMID: 34704822 DOI: 10.2217/bmm-2021-0121] [Reference Citation Analysis]
11 Baldeón ME, Maldonado A, Ochoa-Andrade M, Largo C, Pesantez M, Herdoiza M, Granja G, Bonifaz M, Espejo H, Mora F, Abril-López P, Armijo LKR, Pacheco V, Salazar R, Reinthaller S, Zertuche F, Fornasini M. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection. Transfus Med 2022. [PMID: 35001439 DOI: 10.1111/tme.12851] [Reference Citation Analysis]
12 Mule S, Singh A, Greish K, Sahebkar A, Kesharwani P, Shukla R. Drug repurposing strategies and key challenges for COVID-19 management. J Drug Target 2021;:1-17. [PMID: 34854327 DOI: 10.1080/1061186X.2021.2013852] [Reference Citation Analysis]
13 Akbarzadeh-Khiavi M, Torabi M, Rahbarnia L, Safary A. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. Infection 2021. [PMID: 34902115 DOI: 10.1007/s15010-021-01730-6] [Reference Citation Analysis]
14 Luo L, Qiu Q, Huang F, Liu K, Lan Y, Li X, Huang Y, Cui L, Luo H. Drug repurposing against coronavirus disease 2019 (COVID-19): A review. J Pharm Anal 2021. [PMID: 34513115 DOI: 10.1016/j.jpha.2021.09.001] [Reference Citation Analysis]
15 Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M, Raya-Álvarez E, Velloso-Feijoó ML, López-Medina C, Ramos-Giraldez C, Godoy-Navarrete FJ, Redondo-Rodríguez R, Cabezas-Lucena AM, Morales-Águila M, Romero-Barco CM, Fernández-Nebro A. Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia. Reumatol Clin (Engl Ed) 2021:S1699-258X(21)00089-9. [PMID: 33895100 DOI: 10.1016/j.reuma.2021.02.009] [Reference Citation Analysis]
16 Zheng ZX. Stem cell therapy: A promising treatment for COVID-19. World J Clin Cases 2021; 9(36): 11148-11155 [DOI: 10.12998/wjcc.v9.i36.11148] [Reference Citation Analysis]
17 Tripp RA, Stambas J. Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins. Viruses 2021;13:625. [PMID: 33917411 DOI: 10.3390/v13040625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Vlasov I, Panteleeva A, Usenko T, Nikolaev M, Izumchenko A, Gavrilova E, Shlyk I, Miroshnikova V, Shadrina M, Polushin Y, Pchelina S, Slonimsky P. Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19. Cells 2021;10:3495. [PMID: 34944005 DOI: 10.3390/cells10123495] [Reference Citation Analysis]